Skip to main content

Argenica confident FDA hurdles cleared

47 min ago

Bookmark

Save articles for future reference.
Share to

Perth neurological drug developer Argenica Therapeutics says it has addressed several hurdles which led the US FDA to knock back clinical trials of its flagship ARG-007 stroke drug.

X

To read our articles you will need to either login or subscribe.